Everyone forgets a name or where they put the keys now and then. For families touched by Alzheimer's, those lapses carry a different weight. The disease still has no cure, and today's treatments come with real trade-offs.
A new antibody from Roche called trontinemab now looks able to clear the sticky plaques that build up in the Alzheimer's brain in nearly all treated patients. The side-effect profile also looks milder than for the drugs already on the market.
In the Phase Ib/IIa Brainshuttle AD trial, 92 percent of participants on the higher dose fell below the threshold for amyloid positivity after 28 weeks of treatment. Clinical Trials Arena reported the results from the Alzheimer's Association International Conference in July 2026.
Amyloid-related brain swelling, known as ARIA-E, showed up in fewer than 5 percent of patients across the two tested doses, according to NeurologyLive.
Also read: Your death risk may drop by nearly a quarter with this one diet change
For lecanemab, sold as Leqembi, that same side effect was seen in about 13 percent of patients in its approval trial, according to the prescribing information from Eisai.
How the brain shuttle works
The trick is in the design. Trontinemab is a rebuilt version of an older antibody that latches onto a transport protein called the transferrin receptor.
That receptor acts like a doorway through the blood-brain barrier, carrying the drug across in much larger amounts than ordinary antibodies can manage. The result is that lower doses can reach the brain and strip out plaque faster.
The earlier Phase Ib/IIa results, published in late 2025 in Alzheimer's & Dementia, reported that two higher doses advanced into further testing after amyloid plaque dropped sharply by six months.
Also read: Eating your first meal after noon may raise your death risk by nearly 30%
Approved drugs in the same class, lecanemab and donanemab, also pull amyloid out of the brain. But both carry labels warning of brain swelling and small bleeds visible on MRI, and some patients have to pause or stop treatment because of those changes.
What happens next for patients
Roche has moved to a much larger prevention trial. The Phase 3 study, called PrevenTRON, is enrolling about 1,600 cognitively healthy people aged 55 to 80 who already show amyloid buildup in the brain.
The main question is whether removing plaque before memory loss starts can delay the onset of dementia. Two other Phase 3 trials, named TRONTIER 1 and 2, are testing trontinemab in people with early symptoms.
Early-phase trials with a few dozen participants are not final proof. The 92 percent figure comes from an open-label extension where everyone knows they are on the drug. Only a full randomized Phase 3 trial can show whether patients actually think more clearly on it.
Also read: Mild COVID may have built stronger immune cells in your body than a severe case would have
Anyone noticing new memory lapses, confusion or trouble with familiar tasks should talk to a doctor. Trontinemab is not yet approved by the FDA or any other regulator.
Also read: How eating mango every day may affect your blood sugar and body fat
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.